Mehmet POLATLI, Sevim BAVBEK, Bilun GEMİCİOĞLU, Nurhayat YILDIRIM, Tunçalp DEMİR, Dilşad MUNGAN, Esen KIYAN, Gülfem ELİK, Füsun YILDIZ, Sevgi SARYAL, Arzu YORGANCIOĞLU, Elif ŞEN, Hakan GÜNEN, Haluk TÜRKTAŞ, İpek Kıvılcım OĞUZÜLGEN, Abdullah SAYINER

Ağır astım tedavisi: Uzman görüşü

Ağır astım tüm astımlı hasta popülasyonunun yakla ş ık %10'unuo lu şturur. Astım kontro lünün sorun o ldu ğu b u grup h asta larda acilservis b a şvuru ları, h astane yatışları, iş- güç kayıpları yü kse k oran larda görülür. Dolayısıyla tedavi maliyetleri çok yüksektir ve tümastım maliyetinin %50'si bu grup için h arcanmaktadır. Genellikle yüksek doz in h aler steroid ve uzun etkili beta-2 agonist kombinas-yonu ile kontrol altına alınamayan bu grup h astalarda farklı tedavi seçenekleri denenmektedir. Bu kısa raporda güncel literatür veri-leri derlenerek stan dart tedaviye dirençli a ğır astımlı h astalarda tedavi seçenekleri ülkemiz koşulları da göz önüne alınarak tartışılmışve gün lük klinik pratik için önerilerde bulunulmuştur.

Treatment of severe asthma: Expert opinion

Severe asth matics account 10% of th e all asth matic po pulation. Th ose asth matics wh ose disease is inadequately controlled accoun tfor up to half of th e cost for asth ma, because th ey h ave more emer gency room visits, more h ospital admission an d greater absentee-ism from work. New th erapeutic options were tried in th ose patients wh ose asth ma was uncontrolled with stan dart h igh dose in haledcorticosteroid and lon g actin gbeta-2 a gonsit combination therapy. In th is paper takin g into account th e con ditions of our country,current literature was reviewed an d treatment options was discussed an d graded recommen dations are made for daily clinical practice in patients with severe treatment-refractory asthma.

PDF

___

1. Sch ünemann HJ, Jaeschke R, Coo k DJ, Bria WF, El-So lh AA, Ernst A, et a l. An official ATS statement: grading th e quality of evidence an d stren gth of recommen dations in ATS guidelines an d recommen dations. Am J Respir Crit Care Med 2006 ;174(5):605-14 .
2. Ch un g KF , Wenze l SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. Internationa l ERS/ATS guide lines on definition, eva luation an d treatment of severe asth ma. Eur Respir J 2014 ;43(2):343-73 .
3. Ch un g KF. New treatments for severe treatment-resistan t asth ma: targetin g th e righ t patient. Lancet Respir Me d 201 3 ;1 :84-90.
4. Virchow JC Jr, Prasse A, Na ya I, Summerton L, Harris A. Zafirlu k ast improves asth ma contro l in patients receivin g h igh -dose in h aled corticosteroids. Am J Respir Crit Care Me d 2000 ;162(2 Pt 1):578-85 .
5. Ducharme FM, Lasserson TJ, Cates CJ. Lon g-acting beta2 - agonists versus antileu kotrienes as add-on th erapy to inhaled corticosteroids for chronic asthma. Cochrane Datab ase Sy st Rev 2006(4):CD003137.
6. Lemansk e RF Jr, Mau ger DT, Sorkness CA, Jac kson DJ, Boe h mer SJ, Martinez FD, et a l. Step-u p th erapy for ch il- dren wit h uncontro lled asth ma receivin g in ha le d corticos - teroids. N En gl J Med 2010;362(11):975-85 .
7. Dahlén B, Nizan k owska E, Szcze klik A, Zetterström O, Bochenek G, Kumlin M, et al. Benefits from addin g the 5-lipoxygenase in h ib itor zileuton to conventional th erapy in aspirin-into lerant asth matics. Am J Respir Crit Care Med 1998 ;157(4 Pt 1 ) :1187-94 .
8. Da hlén SE, Malmström K, Nizan kows ka E , Dahlén B, Kuna P, Kowa ls ki M, et al. Im provement of as pirin-into leran t asth ma b y montelu kast, a leu k otriene antagonist: a ran d- omized, dou ble-blin d, placeb o-contro lled trial. Am J Respir Crit Care Med 2002 ;165(1):9-14 .
9. Evans DJ, Taylor DA, Zetterstrom O, Ch ung KF, O'Connor BJ, Barnes PJ. A com parison of low-dose in h a le d b u deso- n ide plus th eoph y lline an d h igh -dose in h aled b udesonide for mo derate asth ma. N Engl J Med 1997;337(20):1412-8 .
10. Ukena D, Harnest U, Sakalauskas R, Ma gyar P, Vetter N, Steffen H, et al. Com parison of addition of theo ph y lline to in h ale d steroid with dou blin g of th e dose of in h aled steroid in asth ma. Eur Respir J 1997;10(12):2754-60 .
11. Spears M, Donnelly I, Jo lly L, Brannigan M, Ito K, McSh arry C, et al. Effect of low-dose th eo phylline plus b ec lometa - sone on lun g function in smo k ers with asth ma: a pilo t stu dy . Eur Respir J 2009;33(5):1010-7. 12. Barnes PJ. T h eo phylline. Am J Respir Crti Care Med 2 01 3:1 88 ; 901 -6 .
13. Guyer AC, Lon g AA. Lon g-actin g antich o linergics in th e treatment of asth ma. Curr Opin Allergy Immuno l 2013; 1 3:3 9 2-9 8.
14. Peters SP, Kunselman SJ, Icitovic N , Moore WC, Pascual R, Ameredes BT, et al. Tiotro pium b romide ste p-u p th era py for adults with uncontrolled asthma. N En gl J Med 2 010 ;363(18):1715-26 .
15. Bateman ED, Kornmann O, Sch midt P, Pivovarova A, En gel M, Fabb ri LM. Tiotro pium is noninferior to salmetero l in maintainin g improved lun g function in B16-Arg/Arg patients with ast h ma. J Allergy Clin Immuno l 2 011 ;128 (2 ) :315-22 .
16. Kerst jens HA, Disse B, Sch rö der-Ba b o W, Bant je TA, Ga hlemann M, Sigmund R, et al. Tiotropium improves lun g function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immuno l 2 011 ;128(2):308-14 .
17. Kerst jens HA, En gel M, Dahl R, Pa ggiaro P, Beck E, Van dewalker M, et al. Tiotro pium in asth ma poorly con - tro lled with stan dard com b ination th erapy. N En gl J Med 2 012 ;367(13):1198-207.
18. Yosh ida M, Nak ano T, Fu kuyama S, Matsumoto T, Eguchi M, Moriwaki A, et al. Effects of tiotropium on lun g function in severe asth matics with or with out em physematous ch an ges. Pu lm Ph armacol T h er 2013;26(2):159-66 .
19. Peters SP, Bleecker ER, Kunselman SJ, Icitovic N, Moore WC, Pascual R, et al. Predictors of response to tiotropium versus salmetero l in ast h matic adu lts. J Allergy C lin Immuno l 2013 ;132(5):1068-74 .
20. Tian JW, Ch en JW, Ch en R, Ch en X. Tiotro pium versus place b o for inade q uate ly contro lled asth ma: a meta-ana ly - sis. Respir Care 2013 [E pu b ah ead of print].
21 . Ra b e KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of b u desonide in com b ination with formoterol for re liever th erapy in asth ma exacerb ations: a ran domised con - tro lled, double-blin d study . Lancet 2006;368(9537):744-53 .
22. Ra b e KF, Pizzic h ini E, Ställb erg B, Romero S, Balanzat AM, Atienza T, et al. Bu desonide/formotero l in a sin gle inh a ler for maintenance an d relief in mild-to-mo derate asthma: a ran domized, dou ble-blin d trial. Ch est 2006 ;129(2):246-56.
23. Scicch itano R, Aa lb ers R, Uk ena D, Manjra A, Fouquert L, Centanni S, et al. Efficac y an d safety of b u desonide/formo - tero l sin gle in h aler th erapy versus a h igh er dose of b u deso - n ide in mo derate to severe asth ma. Curr Me d Res Opin 2 004 ;20 (9 ) :1403-18.
24. O'Byrne PM, Bis gaard H, Go dard PP, Pisto lesi M, Palmqvist M, Zh u Y , et a l. Bu desonide/formotero l com b ination th er- apy as b oth maintenance an d reliever medication in asth- ma. Am J Respir Crit Care Med 2005;171(2):129-36.
25. Kuna P, Peters MJ, Man jra AI, Jorup C, Naya IP, Mart ínez - Jimenez NE, et al. Effect of b u desonide/formotero l mainte - n ance an d re liever th erapy on asth ma exacerb ations. Int J Clin Pract 2007;61(5):725-36.
26. Bousquet J, Boulet LP, Peters MJ, Magnussen H, Quira lte J, Martinez-Aguilar NE, et al. Bu desonide/formotero l for maintenance an d re lief in uncontro lle d asth ma vs. h igh - dose sa lmetero l/fluticasone. Respir Me d 2 007;101 (12 ) :2437-46.
27. Vo gelmeier C, D'Urzo A, Pauwels R, Merino JM, Jaspa l M, Boutet S, et a l. Bu desonide/formotero l maintenance an d re liever th erapy: an effective asth ma treatment option? Eur Respir J 2005;26(5):819-28 .
28. Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergie jko Z, Petruzze lli S, et al. Beclometasone-formotero l as maintenance an d reliever treatment in patients with ast hma: a dou ble-blin d, ran domise d contro lle d trial. Lance t Respir Med 2013;1(1):23-31 .
29. Pate l M , Pilch er J, Pritc h ard A, Perrin K, Travers J, Sh aw D, et al. Efficacy an d safety of maintenance and re liever com - bination budesonide-formoterol inhaler in patients with ast hma at ris k of severe exacerb ations: a ran domised con - trolled trial. Lancet Respir Med 2013;1(1):32-42.
30. Buhl R, Kuna P, Peters MJ, Andersson TL, Naya IP, Peterson S, et al. The effect of budesonide/formoterol maintenance an d reliever th erapy on th e risk of severe ast hma exacerb a - tions followin g episodes of high reliever use: an exploratory ana lysis of two ran domised, contro lled stu dies with com - parisons to stan dard th era py. Respir Res 2012;20;13:59.
31. Ho lgate S, Casale T, Wenze l S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the centra l ro le of IgE in allergic inflammation. J Allergy Clin Immuno l 2005;115(3):459-65.
32. Ro drigo GJ, Neffen H, Castro-Ro driguez JA. Efficacy an d safety of su b cutaneous omalizumab vs. place b o as a dd-on th erapy to corticosteroids for c h ildren an d adu lts with asth ma: a s ystematic review. Ch est 2011;139(1):28-35.
33. Norman G, Faria R, Paton F, L lewelly n A, Fox D, Palmer S, et al. Omalizumab for the treatment of severe persisten t a llergic asth ma: a systematic review an d economic evalua- tion. Health Tec h nol Assess 2013 ;17(52):1-342 .
34. Bousquet J, Cab rera P, Berkman N, Bu hl R, Ho lgate S, Wenzel S , et al. Th e effect of treatment with omalizumab, an anti-IgE antib o dy, on asth ma exacerb ations an d emer- gency medica l visits in patients with severe persisten t asth ma. Allergy 2005;60(3):302-8 .
35. Mo limard M, de Blay F, Didier A, Le Gros V. Effectiveness of omalizuma b (Xo lair) in th e first patients treated in real- life practice in France. Respir Med 2008;102(1):71-6 .
36. Özgür ES, Özge C, Ïlvan A, Nayc ı SA Assessment of lon g- term omalizumab treatment in patients with severe a llergic asth ma long-term omalizuma b treatment in severe asth ma. J Asth ma. 2013 ;50(6):687-94 .
37. Korn S, Th ielen A, Seyfrie d S, Taub e C, Kornmann O, Bu hl R. Omalizuma b in patients with severe persistent a llergic asth ma in a real-life setting in Germany. Respir Med 2009 ;103 (11 ) :1725-31 .
38. Storms W, Bowdish MS , Farrar JR. Omalizumab an d asth- ma control in patients with mo derate-to-severe a llergic asthma: a 6-year pra gmatic data review. Allergy Asthma Proc. 2012 ;33(2):172-7
39. Schumann C, Kropf C, Wibmer T, Rüdiger S, Stoiber KM, T h ielen A, et al. Omalizuma b in patients with severe asth- ma: th e XCLUSIVE stu dy. Clin Respir J 2012;6(4):215-27.
40. Bousquet J, Siergie jko Z, Swiebocka E, Humbert M, Rabe KF, Smith N, et al. Persistency of response to omalizumab th erapy in severe allergic (IgE-mediate d) asth ma. Allergy 2011 ;66(5):671-8.
41. Hanania NA, A lpan O, Hamilos DL, Con demi JJ, Reyes- Rivera I, Zh u J, et a l. Omalizumab in severe allergic asth ma inadeq uately controlled with standard thera py: a rand- omized trial. Ann Intern Med 2011 ;154(9):573-82.
42. de Llano LP, Vennera Mdel C, Álvarez FJ, Medina JF, Borderías L , Pellicer C , et al. Effects of omalizumab in non- atopic asth ma: resu lts from a Spanish mu lticenter registry. J Asth ma 2013 ; 50(3):296-301 .
43. Menze lla F, Faccio lon go N, Piro R, Formisano D, Ro ggeri A, Simonazzi A, et a l. Clinical an d pharmacoeconomic aspects of omalizumab: a 4-year follow-up. Ther Adv Respir Dis 2012;6(2):87-95.
44. Camargo CA Jr, Weiss ST, Zh an g S, Willett WC, Speizer FE. Prospective stu dy of b ody mass in dex, weigh t ch an ge, an d risk of a du lt-onset asth ma in women. Arc h Intern Me d 1999 ; 22 ;159(21):2582-8.
45. Zarga A, Ulrik CS. Obesity and asthma: a coincidence or a causa l re lationsh ip? A sy stematic review Respiratory Me dicine 2013;1:14 .
46. Ho lguin F, Bleeck er ER, Busse WW, Ca lh oun WJ, Castro M, Erzurum SC, et a l. O b esity an d asth ma: an association mo difie d b y a ge of asth ma onset. J Allergy Clin Immuno l 2011;127(6):1486-93.
47. Side leva O, Black K, Dixon AE. Effects of o b esity an d weigh t loss on airway ph ysio lo gy and inflammation in asth ma. Pu lm Ph armaco l T h er 2013 ; 26(4):455-8.
48. Dixon AE, Clerisme-Beaty EM, Su gar EA, Co h en RI, Lan g JE, Brown ED, et a l. Effects of o b structive slee p a pnea an d gastroesoph a gea l reflux disease on asth ma contro l in o b e - sity. J Asth ma 2011;48(7):707-13.
49. Chun g KF, Wenze l SE, Broze k JL, Bush A, Castro M, Sterk PJ, et a l. Internationa l ERS/ATS guide lines on definition, eva luation an d treatment of severe asthma. Eur Respir J 2014 ;43 (2 ):343-73.
50 . Ha ldar P, Pavord ID, Sh aw DE, Berry MA, T h omas M, Brigh tlin g CE, et a l. Cluster ana lysis an d clinica l asth ma phe - notypes. Am J Respir Crit Care Me d 2008;178(3):218-24.
51. Novosa d S, Kh an S, Wo lfe B, Kh an A. Ro le of o b esity in asth ma contro l, th e O b esity-Asth ma Ph enotype Journa l o f Allergy 2013, Artic le ID 538642 .
52. Jue l CT, Ali Z, Nilas L, Ulrik CS. Asth ma an d o b esity: does weigh t loss improve asth ma control? a systematic review J Asth ma Allergy 2012;5:21-6.
53. Manisca lco M , Ze dda A, Faraone S, Cerb one MR, Cristiano S, Giardie llo C, et a l. Weigh t loss an d asth ma contro l in severely obese asthmatic females. Respir Me d 2008 ;102 (1 ):102-8.
54. Stenius-Aarnia la B, Poussa T , Kvarnström J, Grön lun d EL , Ylika hri M, Musta jo ki P. Imme diate an d lon g term effects o f weigh t re duction in o b ese people with asth ma: ran - domise d contro lle d stu dy . BMJ 2000;320(7238):827-32.
55. Baruwa P, Sarma h KJ. O b esity an d asth ma. Lung In dia 2013 ;30(1):38-46 .
56. Re ddy RC, Ba ptist AP, Fan Z, Carlin AM, Birk me yer NJ. Th e effects of b ariatric surgery on asth ma severity. O b es Surg 2011 ;21(2):200-6.
57. Sikka N, We gienka G, Havstad S, Genaw J, Carlin AM, Zoratti E. Respiratory me dication prescriptions b efore an d after bariatric surgery. Ann Allergy Asthma Immuno l 2010 ;104 (4 ):326-30.
58. Adeniyi FB ,Youn g TE. Weigh t loss interventions for ch ron - ic asth ma. Coch rane Data b ase Syst Rev. 2012 Ju l 11 ;7: CD00933 9
59. Moreira A, Bonini M , Garcia-Larsen V, Bonini S, De l Giacco SR, Agache I, et al. Weight loss interventions in asth ma: EAACI evidence-b ase d clinica l practice guide line (part I). Allergy 2013;68(4):425-39.
60. Brusse lle GG, Joos G. Is th ere a ro le for macro lides in severe asth ma? Curr Opin Pu lm Me d 2014; 20: 95-10 2
61. Reiter J, Demire l N, Men dy A, Gasana J, Vieira ER, Co lin AA, et a l. Macro lides for th e long-term mana gement o f asth ma--a meta-ana lysis of ran domize d c linica l tria ls. Allergy 2013;68(8):1040-9.
62. Sim pson JL, Powe ll H, Bo yle MJ, Scott RJ, Gib son PG. Clarith romycin targets neutroph ilic airway inflammation in refractory asth ma. Am J Respir Crit Care Me d 2 008 ;177(2):148-55 .
63. Ha hn DL, Grasmic k M, Hetze l S, Ya le S ; AZMATICS (AZith roMycin-Asth ma Tria l In Community Settin gs) Stu dy Grou p. Azithromy cin for b ronch ia l asth ma in a du lts: an effectiveness tria l. J Am Board Fam Me d 2012 ;25(4):442-59 .
64. Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Rin goet V, et al. Azithromycin for prevention of exacerb ations in severe asth ma (AZISAST ): a mu lticen - tre ran domise d dou ble- blin d place b o-contro lle d tria l. T h orax 2013 Apr;68(4):322-9 .
65. T h omas PS, Yates DH , Barnes PJ. Tumor necrosis factor- a lph a increases airwa y responsiveness an d sputum neutro - ph ilia in norma l human su bjects. Am J Respir Crit Care Me d 1995 ;152:76-80 .
66. Yin g S, Ro b inson DS, Varney V, Men g Q, Tsicopou los A, Moq b e l R, et a l. TNF-a lph a mRNA expression in a llergic inflammation. Clin Exp Allergy 1991;21(6):745-50.
67. Howarth PH, Ba b u KS, Arsh a d HS, Lau L, Buckle y M, McConne ll W, et a l. Tumour necrosis factor (TNFa lph a) as a nove l th erapeutic target in symptomatic corticosteroid de pendent asthma. Thorax 2005 Dec;60(12):1012-8.
68 . Berry MA, Harga don B, S h e lley M, Parker D, Sh aw DE, Green RH, et al. Evidence of a role of tumor necrosis fac- tor a lph a in refractory asth ma. N En gl J Me d 2006 ; 354 (7):697-708 .
69. Mor jaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, Ho lgate ST. T h e ro le of a so luble TNFa lph a receptor fusion protein (etanerce pt) in corticosteroid refractory asth ma: a dou ble blind, ran domise d, place b o controlle d tria l. Th ora x 2008 ;63 (7):584-91 .
70. Ho lgate ST, Noonan M, Ch anez P, Busse W, Dupont L, Pavord I, et a l. Efficacy an d safety of etanerce pt in mo der- ate-to-severe asth ma: a ran domise d, contro lle d tria l. Eu r Respir J 2011;37(6 ):1352-9 .
71. Wenzel SE, Barnes PJ, B leec ker ER, Bousq uet J, Busse W, Da hlén SE, et a l. A ran domized, dou ble- blin d, place b o- contro lled stu dy of tumor necrosis factor-a lpha block a de in severe persistent asth ma. Am J Respir Crit Care Me d 2009 ;179 (7 ) :549-58 .
72. James AL, Elliot JG , Jones RL, Carro ll ML, Maua d T , Bai TR , et a l. Airwa y smooth muscle hypertro phy an d hyperplasia in asth ma. Am J Respir Crit Care Med 2012;185(10):1058-64 .
73. Dane k CJ, Lom b ard CM, Dun gworth DL, Cox PG, Miller JD, Biggs MJ, et a l. Reduction in airway h yperresponsive - n ess to meth ac h o line b y th e application of RF energy in do gs. J Appl P h ysio l (1985) 2004;97(5):1946-53.
74. Miller JD, Cox G, Vincic L , Lom b ard CM , Loomas BE, Danek CJ. A prospective feasib ility stu dy of b ronch ia l th ermo plasty in th e h uman airwa y. Ch est 2005;127(6):1999-2006 .
75. Cox G, Miller JD, McWilliams A, Fitz gera ld JM, Lam S. B ronch ia l th ermoplasty for asth ma. Am J Respir Crit Care Me d 2006 ;173(9):965-9 .
76. Cox G, T h omson NC, Ru b in AS , Niven RM , Corris PA, Siersted HC, et a l.; AIR Tria l Stu dy Grou p. Asth ma contro l durin g th e year after b ronch ia l th ermoplasty. N En gl J Me d 2007 ;356 (13 ) :1327-37.
77. Pavord ID, Cox G, T h omson NC, Ru b in AS , Corris PA, Niven RM, et a l.; RISA Tria l Stu dy Grou p. Safety an d effi- cac y of b ronch ia l th ermo plasty in sy m ptomatic, severe asth ma. Am J Respir Crit Care Me d 2007;176(12):1185-91 .
78. Castro M , Ru b in AS, Lavio lette M , Fiterman J, De An dra de Lima M, S h a h PL, et a l.; AIR2 Tria l Stu dy Grou p. Effectiveness an d safety of b ronch ia l th ermo plasty in the treatment of severe asth ma: a mu lticenter, ran domize d, dou ble-blin d, sh am-contro lle d clinica l tria l. Am J Res pir Crit Care Med 2010 ;181(2):116-24 .
79. T h omson NC, Ru b in AS , Niven RM, Corris PA, Sierste d HC, Olivenstein R, et al.; AIR Trial Study Group. Lon g -term (5 y ear) safety of b ronc h ia l th ermo plasty: Asth ma Intervention Researc h (AIR ) tria l. BMC Pu lm Me d 2011 ;11:8 .
80. Wec h sler ME, Lavio lette M, Ru b in AS, Fiterman J, La pa e Silva JR , S ha h PL , et a l. ; Asth ma Intervention Researc h 2 Trial Study Group. Bronchial thermoplasty: Lon g -term safety an d effectiveness in patients with severe persisten t asthma. J Allerg y Clin Immuno l 2013;132(6):1295-302.
81. Wa h idi MM, Kraft M. Bronch ia l th ermoplasty for severe asthma. Am J Respir Crit Care Med 2012:185(1):709-14.
82. S hesh a dri A, Castro M, Chen A. Bronc h ia l th ermo plasty: a n ove l th era py for severe asth ma. Clin Ch est Me d 2013; 3 4:4 37-44 .
83. Lec kie MJ, ten Brin k e A, Kh an J, Diamant Z, O'Connor BJ, Wa lls CM, et a l. Effects of an interleu kin-5 bloc king mono - c lona l antib o dy on eosino ph ils, airwa y hyper-res ponsive- n ess, an d th e late asth matic response. Lance t 2000 ;356 (9248 ) :2144-8 .
84. F loo d-Pa g e P, Swenson C, Faiferman I, Matth ews J, Williams M, Brannic k L, et a l.; Internationa l Mepo lizuma b Stu dy Grou p. A stu dy to eva luate safety an d efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176(11):1062-71.
85. Ha ldar P, Brigh tling CE, Harga don B, Gupta S, Monteiro W, Sousa A, et a l. Me po lizuma b and exacerb ations o f refractory eosinoph ilic asth ma. N En gl J Me d 2009 ;360 (10 ) :973-84.
86. Nair P, Pizzich ini MM, K jarsgaard M, Inman MD, E fth imia dis A, Pizzich ini E, et a l. Mepo lizuma b for pre d- n isone-de pen dent asth ma with sputum eosino ph ilia. N E ngl J Me d 2009;360(10):985-93.
87. Pavord ID , Korn S , Howarth P , B leeck er ER , Bu hl R , Keene ON, et al. Mepolizumab for severe eosino philic asthma (DREAM): a mu lticentre, dou ble-blin d, placeb o-controlled tria l. Lancet 2012 ;380(9842):651-9.
88. Castro M, Math ur S, Hargreave F, Bou let LP, Xie F, Youn g J, et a l.; Res-5-0010 Stu dy Grou p. Reslizuma b for poorly contro lled, eosino philic asth ma: a ran domized, placeb o- contro lle d stu dy. Am J Res pir Crit Care Me d 2011 ;184 (10 ) :1125-32 .
89. Corren J, Lemansk e RF, Hanania NA, Koren blat PE, Parse y MV, Arron JR , et a l. Leb rik izuma b treatment in a du lts with asth ma. N En gl J Med 2011;365(12):1088-98 .
90 . Piper E, Brigh tlin g C, Niven R, O h C, Fa ggioni R, Poon K, et a l. A ph ase II place b o-contro lle d stu dy of tra lo kinuma b in mo derate-to-severe asth ma. Eur Respir J 2013;41(2):330-8.
91. Wenzel S, Ford L, Pearlman D, S pector S, Sh er L, Sko b ieran da F, et a l. Du piluma b in persistent asth ma with elevated eosinoph il levels. N En gl J Med 2013;368(26):2455-66.
92. Nair P, Ga g a M, Zervas E, Ala gh a K, Harg reave FE, O'Byrne PM, et a l.; Stu dy Investigators. Safety an d efficac y of a CXCR2 anta g onist in patients with severe asth ma an d sputum neutro ph ils: a ran domized, placeb o-controlled clinical trial. Clin Exp Allergy 2012;42(7):1097-103.